This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BUFFALO, N.Y., Nov. 21, 2013 (GLOBE NEWSWIRE) --
Cleveland BioLabs, Inc. (Nasdaq:CBLI) and
Incuron, LLC, a joint venture between CBLI and Bioprocess Capital Ventures today announced a poster presentation at the 2013 Society for Neuro-Oncology Meeting, held
November 21-24, 2013 in San Francisco, California.
A poster titled, "CBL0137 significantly increases survival in orthotopic models of glioblastoma multiforme alone and in combination with temozolomide" will be presented on November 23. The poster describes the effects of CBL0137 on murine orthotopic xenograft models of glioblastoma multiforme following intravenous or oral administration of CBL0137 as a single agent or in combination with temozolomide, the current standard care chemotherapeutic drug for treatment of glioblastoma. CBL0137 was found to significantly improve survival of tumor-bearing animals in two different orthotopic models of glioblastoma, and in both models, intravenous administration of CBL0137 was more effective than oral administration. In these animal studies, CBL0137 was shown to be effective against temozolomide sensitive and resistant tumor models. Additionally, in a temozolomide sensitive model, the combination of CBL0137 and temozolomide increased animal survival to a greater extent than each of the drugs administered independently. These data suggest that CBL0137 may have the potential to provide clinical benefit in the treatment of glioblastoma.
CBL0137 is being developed by Incuron, LLC. Dosing is ongoing in a multi-center Phase 1 trial evaluating intravenous administration of CBL0137 in patients with metastatic or unresectable advanced solid tumors and lymphomas in the U.S. In addition, a Phase 1 study of oral administration of CBL0137 in patients with advanced solid tumors that are resistant or refractory to standard treatment is currently being conducted in the Russian Federation.
For more information about the 2013 Society for Neuro-Oncology Meeting, please refer to
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep understanding of molecular and cellular mechanisms of biological stress responses to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia for Medical Research and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at
http://www.cbiolabs.comAbout Incuron, LLC
Incuron, LLC is a Russian Federation based joint venture founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Incuron is developing CBL0102 and CBL0137 for oncology and orphan indications. To learn more about Incuron, LLC, please visit the company's website at
This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the conduct and results of our various clinical trials; our ability to successfully develop and commercialize our therapeutic products; the performance of our partners and subsidiaries with respect to ongoing development of our therapeutic products; our and our partners' ability to obtain and maintain sufficient funding for developing and commercializing therapeutic products; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These factors include, among others, the decisions of third parties regarding whether or not to fund the Company through grants; the Company's failure to successfully and timely develop existing and new products; the Company's collaborative relationships and the financial risks related thereto; the Company's inability to obtain regulatory approval in a timely manner or at all; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's ability to comply with its obligations under license agreements; the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.